# MaxCyte Raises 2026 Revenue Guidance Following Strong Third Quarter

- URL: https://stocks.freetheai.org/news/maxcyte-raises-2026-revenue-guidance-following-strong-third-quarter-af1ebe
- Published: 2026-10-14T12:05:00Z
- Category: earnings; sentiment: bullish; impact: medium
- Symbols: [NASDAQ:MXCT](https://stocks.freetheai.org/symbols/NASDAQ-MXCT)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Cell-engineering provider MaxCyte, Inc. (MXCT) released preliminary third-quarter 2026 financial results and raised its full-year revenue outlook. Preliminary core business revenue for the quarter ended September 30 reached approximately $8.1 million, up 26% from the third quarter of 2025. Strategic Platform License revenue added more than $1.0 million, supported by a $1.0 million milestone payment.

Following the strong performance, MaxCyte increased its full-year 2026 revenue forecast to approximately $34 million, up from its previous target of $30 million to $32 million. Core business revenue for the year is now expected to reach approximately $28 million, while strategic license revenue is projected at $6 million. Management attributed the gains to accelerated instrument orders from a large customer and double-digit core business growth.

Complete financial results and royalty revenue data will be released when the company holds its third-quarter earnings conference call on November 10, 2026, at 4:30 p.m. Eastern Time.

## Key points

- MaxCyte raised its full-year 2026 revenue guidance to approximately $34 million, up from prior expectations of $30 million to $32 million.
- Preliminary core business revenue for the third quarter of 2026 rose 26% year-over-year to approximately $8.1 million.
- Strategic Platform License revenue reached over $1.0 million in the quarter, backed by a $1.0 million milestone payment.
- Full-year core business revenue guidance was lifted to approximately $28 million, compared to $25 million to $27 million previously.
- Final third-quarter financial results and royalty details will be reported on November 10, 2026.

## Questions and answers

### What is MaxCyte's updated revenue guidance for 2026?

MaxCyte raised its full-year 2026 revenue guidance to approximately $34 million, up from its prior forecast of $30 million to $32 million. This includes approximately $28 million in core business revenue and $6 million in strategic platform license revenue.

### How much revenue did MaxCyte report for the third quarter of 2026?

MaxCyte reported preliminary third-quarter 2026 core business revenue of approximately $8.1 million, an increase of 26% year-over-year. Strategic Platform License revenue contributed more than $1.0 million during the quarter.

### When will MaxCyte release its complete third-quarter 2026 results?

MaxCyte will report its full third-quarter 2026 financial results and host a webcast conference call on November 10, 2026, at 4:30 p.m. Eastern Time.